1. Scrip
  2. >>Therapy Areas

Galderma set to launch Nuvo's Pliaglis in EU

 
• By Gemma Sharman

Dermatology company Galderma has received its first three EU marketing licences for its topical pain drug Pliaglis (tetracaine and lidocaine), with plans to launch in the first half of 2013.

Dermatology company Galderma has received its first three EU marketing licences for its topical pain drug Pliaglis (tetracaine and lidocaine), with plans to launch in the first half of 2013.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapeutic Category

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.